# Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I

> **NCT05449405** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dr. Ferrer BioPharma** · enrollment: 101 (actual)

## Conditions studied

- COVID-19
- Symptoms and Signs
- COVID-19 Pandemic
- Coronavirus Disease 2019
- Coronavirus Infections

## Interventions

- **COMBINATION_PRODUCT:** Chlorpheniramine Maleate 1% Nasal Spray
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT05449405
- **Lead sponsor:** Dr. Ferrer BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-07
- **Primary completion:** 2022-03-11
- **Final completion:** 2022-03-11
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05449405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05449405, "Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05449405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*